Evidence map›Paper›PMID 37979935›Full record

ArticleAcademic pediatrics2024

Impact of the COVID-19 Pandemic on Childhood Lead Testing and Blood Lead Levels.

Ryan C L Brewster, Amee D Azad, Keith Acosta, Amy Starmer, Eli Sprecher, Corinna Rea, Kathryn P Gray, Shannon Regan, Joseph Wilson, Frehiwot Bayuh and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Academic pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ryan C L BrewsterDepartment of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, KP Gray, S Reagan, F Bayuh, and M Hauptman), Boston Children's Hospital, Boston, Mass; Department of Pediatrics (RCL Brewster and N Buncher), Boston Medical Center, Boston, Mass; Department of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, and M Hauptman), Harvard Medical School, Boston, Mass. Electronic address: ryan.brewster@childrens.harvard.edu.
Amee D AzadDepartment of Ophthalmology (AD Azad), Massachusetts Eye and Ear, Boston, Mass.
Keith AcostaDepartment of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, KP Gray, S Reagan, F Bayuh, and M Hauptman), Boston Children's Hospital, Boston, Mass; Department of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, and M Hauptman), Harvard Medical School, Boston, Mass.
Amy StarmerDepartment of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, KP Gray, S Reagan, F Bayuh, and M Hauptman), Boston Children's Hospital, Boston, Mass; Department of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, and M Hauptman), Harvard Medical School, Boston, Mass.
Eli SprecherDepartment of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, KP Gray, S Reagan, F Bayuh, and M Hauptman), Boston Children's Hospital, Boston, Mass; Department of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, and M Hauptman), Harvard Medical School, Boston, Mass.
Corinna ReaDepartment of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, KP Gray, S Reagan, F Bayuh, and M Hauptman), Boston Children's Hospital, Boston, Mass; Department of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, and M Hauptman), Harvard Medical School, Boston, Mass.
Kathryn P GrayDepartment of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, KP Gray, S Reagan, F Bayuh, and M Hauptman), Boston Children's Hospital, Boston, Mass; Institutional Centers of Clinical and Translational Research (KP Gray), Boston Children's Hospital, Boston, Mass.
Shannon ReganDepartment of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, KP Gray, S Reagan, F Bayuh, and M Hauptman), Boston Children's Hospital, Boston, Mass.
Joseph WilsonHarvard T.H. Chan School of Public Health (J Wilson), Boston, Mass.
Frehiwot BayuhDepartment of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, KP Gray, S Reagan, F Bayuh, and M Hauptman), Boston Children's Hospital, Boston, Mass.
Noah BuncherDepartment of Pediatrics (RCL Brewster and N Buncher), Boston Medical Center, Boston, Mass; Region 1 New England Pediatric Environmental Health Specialty Unit (PEHSU) (N Buncher and M Hauptman), Boston, Mass.
Marissa HauptmanDepartment of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, KP Gray, S Reagan, F Bayuh, and M Hauptman), Boston Children's Hospital, Boston, Mass; Department of Pediatrics (RCL Brewster, K Acosta, A Starmer, E Sprecher, C Rea, and M Hauptman), Harvard Medical School, Boston, Mass; Region 1 New England Pediatric Environmental Health Specialty Unit (PEHSU) (N Buncher and M Hauptman), Boston, Mass.
Boston Children's Hospital · USBoston Medical Center · USHarvard University · USMassachusetts Eye and Ear Infirmary · US

Funding

Air Pollution, Stress and Asthma Morbidity Risk: Role of Biological and Geospatial MarkersK23ES031663 · NIEHS · BOSTON CHILDREN'S HOSPITAL · PI HAUPTMAN, MARISSA · 2021 to 2025
$984k
ATSDR CDC HHS R01 TS000296NIEHS NIH HHS K23 ES031663
6 · The paper itself

Abstract

objectiveTo evaluate the effect of the COVID-19 pandemic on childhood lead testing and blood lead levels.

methodsA retrospective analysis of lead tests and results was performed across 3 urban medical centers during the pre-COVID-19 (March 10, 2019-March 9, 2020) and COVID-19 (March 10, 2020-March 10, 2022) periods. Interrupted time series analysis with quasi-Poisson regression was used to evaluate changes in lead testing between study periods. The relationship between sociodemographic features with detectable (≧2 µg/dL) and elevated (≧3.5 µg/dL) blood lead levels (BLLs) was assessed with multivariable logistic regression.

resultsAmong a total of 16,364 lead tests across 10,362 patients, weekly testing rates significantly decreased during COVID-19 (relative risk (RR) 0.64, 95% (confidence interval) CI 0.53-0.78). Census tracts with the greatest proportion of pre-1950s housing had a stronger association with detectable BLLs during the COVID-19 period (pre-COVID-19 adjusted odds ratio (aOR) 1.73, 95% CI 1.35-2.20; aOR 2.58, 95% CI 2.13-3.12; interaction P value .014). When limited to 1 year following COVID-19 (March 10, 2020-March 10, 2021), the association between both elevated BLLs (pre-COVID-19: aOR 1.49, 95% CI 0.87-2.53; COVID-19: aOR 3.51, 95% CI 1.98-6.25; interaction P value .032) and detectable BLLs with pre-1950s housing were greater during the COVID-19 period (pre-COVID-19: aOR 1.73, 95% CI 1.35-2.20; COVID-19: aOR 2.56, 95% CI 1.95-3.34; interaction P value .034).

conclusionsThe COVID-19 pandemic led to a significant reduction in lead surveillance and magnified the effect of known risk factors for lead exposure. Concerted clinical, public health, and community advocacy are needed to address care gaps and excess cases of lead poisoning.

Indexed as

COVID-19LeadLead PoisoningAdolescentChildChild, PreschoolFemaleHumansInfantInterrupted Time Series AnalysisLogistic ModelsMalePandemicsRetrospective StudiesSARS-CoV-2Leadenvironmental healthhealth equitylead poisoning

Identifiers

PMID37979935
PMCPMC11949626
OpenAlexW4388765499

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.